ArticleOncogene2005
Transcriptional cross-regulation of RUNX1 by RUNX3 in human B cells.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 94 citations in OpenAlex.
- Immunoprofiling, sex- and age-related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma.British journal of haematology · 2026Article
- Cisformer: a scalable cross-modality generation framework for decoding transcriptional regulation at single-cell resolution.Genome biology · 2025Article
- Fish species lifespan prediction from promoter cytosine-phosphate-guanine density.Molecular ecology resources · 2025Article
- RUNX3 inhibits KSHV lytic replication by binding to the viral genome and repressing transcription.Journal of virology · 2024Article
- Proteogenomic analysis reveals cytoplasmic sequestration of RUNX1 by the acute myeloid leukemia-initiating CBFB::MYH11 oncofusion protein.The Journal of clinical investigation · 2023Article
- Inferring gene regulatory network from single-cell transcriptomes with graph autoencoder model.PLoS genetics · 2023Article
- Runt-related transcription factors in human carcinogenesis: a friend or foe?Journal of cancer research and clinical oncology · 2023Review
- Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma.Molecular cancer · 2023Article
- Review
- RUNX3 overexpression inhibits normal human erythroid development.Scientific reports · 2022Article
- Review
- Super-enhancers for RUNX3 are required for cell proliferation in EBV-infected B cell lines.Gene · 2021Article
- Runx1 and Runx3 drive progenitor to T-lineage transcriptome conversion in mouse T cell commitment via dynamic genomic site switching.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Genetic Regulation of Immunoglobulin G Glycosylation.Experientia supplementum (2012) · 2021Article
- Glycosylation of immunoglobulin G is regulated by a large network of genes pleiotropic with inflammatory diseases.Science advances · 2020Article
- Identification of human silencers by correlating cross-tissue epigenetic profiles and gene expression.Genome research · 2019Article
- Trans-Ethnic Mapping ofInternational journal of molecular sciences · 2018Article
- Unique N-terminal sequences in two Runx1 isoforms are dispensable for Runx1 function.BMC developmental biology · 2017Article
- Core binding factor (CBF) is required for Epstein-Barr virus EBNA3 proteins to regulate target gene expression.Nucleic acids research · 2017Article
- CD74 is a novel transcription regulator.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RUNX transcription factors are important in development and in numerous types of human cancer. They act as either transcriptional activators or repressors and can be proto-oncogenes or tumour suppressors. Understanding their regulation and interaction may explain how RUNX factors contribute to such different and often opposing biological processes. We show that RUNX3 regulates RUNX1 expression, contributing to the mutually exclusive expression of RUNX3 and RUNX1 in human B lymphoid cell lines. RUNX3 repressed the RUNX1 P1 promoter by binding specifically to conserved RUNX sites near the transcription start of the promoter. siRNA inhibition of RUNX3 in lymphoblastoid cells resulted in increased RUNX1 expression, indicating that continuous expression of physiological levels of RUNX3 is required to maintain repression. Furthermore, expression of RUNX3 was required for efficient proliferation of B cells immortalized by Epstein-Barr virus. Cross-regulation between different RUNX family members is therefore a means of controlling RUNX protein expression and must now be considered in the interpretation of pathological changes due to loss of RUNX3 tumour suppressor function or following gene duplication or translocation events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.